Results 211 to 220 of about 910,855 (274)
Genetic Analysis of Candida albicans Filamentation by the Iron Chelator BPS Reveals a Role for a Conserved Kinase-WD40 Protein Pair. [PDF]
J Fungi (Basel)Pinsky M, Kornitzer D.
europepmc +1 more source
The Fungal Iron Chelator Desferricoprogen Inhibits Atherosclerotic Plaque Formation. [PDF]
Int J Mol Sci, 2020 Potor L +14 more
europepmc +1 more source
Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial. [PDF]
BMJ OpenPremawardhena A +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
European Journal of Haematology, 2023
Abstract Iron overload is a pathological condition resulting from a congenital impairment of its regulation, increased intestinal iron absorption secondary to bone marrow erythroid hyperplasia, or a chronic transfusional regimen. In normal conditions, intracellular and systemic mechanisms contribute to maintaining iron balance.
Antonella Bruzzese +11 more
openaire +2 more sources
Abstract Iron overload is a pathological condition resulting from a congenital impairment of its regulation, increased intestinal iron absorption secondary to bone marrow erythroid hyperplasia, or a chronic transfusional regimen. In normal conditions, intracellular and systemic mechanisms contribute to maintaining iron balance.
Antonella Bruzzese +11 more
openaire +2 more sources
Blood Reviews, 1990
Adequate iron chelation in thalassaemia has resulted in a striking improvement in survival, with a reduction of cardiac mortality at age 15 years from 14-3%, and a predicted survival at age 36 years of 85%. Long term desferrioxamine (DF) therapy in thalassaemic children should be started between 2-4 years of age.
C, Hershko, A, Pinson, G, Link
openaire +3 more sources
Adequate iron chelation in thalassaemia has resulted in a striking improvement in survival, with a reduction of cardiac mortality at age 15 years from 14-3%, and a predicted survival at age 36 years of 85%. Long term desferrioxamine (DF) therapy in thalassaemic children should be started between 2-4 years of age.
C, Hershko, A, Pinson, G, Link
openaire +3 more sources
Annual Review of Medicine, 2009
Deferoxamine (DFO) was the standard of care for transfusional iron overload for >40 years, requiring subcutaneous infusion for 8–12 h/day, 5–7 days/week. Oral iron chelators are an important development, offering the potential to improve compliance and patients’ quality of life.
M.D. Cappellini, P. Pattoneri
openaire +2 more sources
Deferoxamine (DFO) was the standard of care for transfusional iron overload for >40 years, requiring subcutaneous infusion for 8–12 h/day, 5–7 days/week. Oral iron chelators are an important development, offering the potential to improve compliance and patients’ quality of life.
M.D. Cappellini, P. Pattoneri
openaire +2 more sources